Studie zur Bewertung der Wirksamkeit und Sicherheit von CNP520 bei Teilnehmern mit Risiko für das Auftreten von klinischen Symptomen der Alzheimer-Krankheit (AK)

Drug: CNP520 50mg;Drug: CNP520 15mg;Other: Matching placebo

Inclusion Criteria:

- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.

- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential

- Cognitively unimpaired as evaluated by memory tests performed at screening.

- Participant's willingness to have a study partner.

- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).

Exclusion Criteria:

- Any disability that could have prevented the participants from completing all study
requirements. -

- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.

- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.

- History of malignancy of any organ system, treated or untreated, within the past 60
months.

- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).

- Contraindication or intolerance to MRI.

- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.

- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.

- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.

- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.

- Current clinically significant ECG findings.

- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.